Aravax

Aravax is a clinical-stage biotechnology company developing next-generation specific immunotherapies for food allergy.

Its lead candidate, PVX108, is a synthetic peptide-based therapy designed to desensitise peanut-allergic patients by targeting the T cells that drive allergic responses, without triggering acute reactions during treatment.

The UK subsidiary, based at Oxford Science Park, leads pharmaceutical and CMC development for the company's peptide drug substances as PVX108 progresses towards Phase 3.